Israel vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Israel
100.0%
in 2024
Mus
100.0%
in 2024
Israel rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Israel
- Mus
How they compare
Israel currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 5 times across 12 shared years of data; in 2008 it was Israel ahead.
Israel ranks 1st and Mus ranks 1st of 144 countries.
Across the 3 decades both report, Israel averaged higher in 2 and Mus in 1.
Head to head by decade
| Decade | Israel | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 68.0% | 60.5% | 7.5% | Israel |
| 2010s | 100.0% | 87.0% | 13.0% | Israel |
| 2020s | 98.2% | 100.0% | 1.8% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Israel or Mus?
- Israel, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Israel and Mus?
- 0.0%, with Israel ahead.
- How many years of comparable data are there for Israel and Mus?
- 12 years are reported by both, from 2008 to 2024.
- How do Israel and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Israel ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.